ConductScience.org, home

Paper25566959

Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.

Greife A and 5 others. Tumour Biol, 2015. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Papers, record 25566959. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25566959

Download JSON
Cell line
BFTC-905-DOXO-II1 paper
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
PubMed
Journal
Tumour Biol
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
0.81
iCite
Revised in PubMed
2018-11-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Greife AAnnemarie
2Tukova JJitka
3Steinhoff CChristine
4Scott SDSimon D
5Schulz WAWolfgang A
6Hatina JJiri

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
DoxorubicinMajor topic
Drug Resistance, NeoplasmMajor topic
Urinary Bladder NeoplasmsMajor topic
Biosynthetic Pathways
Cell Line, Tumor
Cell Survival
Drug Synergism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inhibitory Concentration 50
Mevalonic Acid
Simvastatin
Transcriptome

Source PubMed

Download CSV of topics

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11822001The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline.Sel Cancer Ther1991https://conductscience.org/library/papers/1822001PubMed
29477189
Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Int J Urol1997https://conductscience.org/library/papers/9477189PubMed
320477901The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells.J Cell Mol Med2011https://conductscience.org/library/papers/20477901PubMed
420696928Dysregulation of the mevalonate pathway promotes transformation.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20696928PubMed
512923562In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.Gene Ther2003https://conductscience.org/library/papers/12923562PubMed
618840072Molecular pathogenesis and diagnostics of bladder cancer.Annu Rev Pathol2009https://conductscience.org/library/papers/18840072PubMed
724582968Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.Pharmacol Ther2014https://conductscience.org/library/papers/24582968PubMed
88567404Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.Jpn J Cancer Res1995https://conductscience.org/library/papers/8567404PubMed
915161671Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.Blood2004https://conductscience.org/library/papers/15161671PubMed
1019760159Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.Invest New Drugs2010https://conductscience.org/library/papers/19760159PubMed
1123040256New therapeutic challenges in advanced bladder cancer.Semin Oncol2012https://conductscience.org/library/papers/23040256PubMed
1223038228Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Onkologie2012https://conductscience.org/library/papers/23038228PubMed
1314501774
Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
J Urol2003https://conductscience.org/library/papers/14501774PubMed
1422310279Targeting tumor cell metabolism with statins.Oncogene2012https://conductscience.org/library/papers/22310279PubMed
158712703Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan.Anticancer Res1996https://conductscience.org/library/papers/8712703PubMed
1621398618Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.J Natl Cancer Inst2011https://conductscience.org/library/papers/21398618PubMed
1723395802Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.J Urol2013https://conductscience.org/library/papers/23395802PubMed
1819508172Targeting the mevalonate pathway for improved anticancer therapy.Curr Cancer Drug Targets2009https://conductscience.org/library/papers/19508172PubMed
1915818381Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.Cancer Gene Ther2005https://conductscience.org/library/papers/15818381PubMed
208100862Evaluation of multiple drug resistance in human bladder cancer cell lines.J Urol1993https://conductscience.org/library/papers/8100862PubMed

See all 39 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
41226440The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research.Int J Mol Sci2025https://conductscience.org/library/papers/41226440PubMed
40947699The Impact of IGFBP6 Knockdown on Cholesterol Metabolism in Breast Cancer Cells.Curr Med Chem2026https://conductscience.org/library/papers/40947699PubMed
40916434Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.Protein Pept Lett2025https://conductscience.org/library/papers/40916434PubMed
40353763Repurposing Amiodarone for Bladder Cancer Treatment.Cancer Res Commun2025https://conductscience.org/library/papers/40353763PubMed
39838687The Expression of the LDLR, LDLRAP1, and PCSK9 Genes has Prognostic Significance in Triple-negative Breast Cancer.Curr Med Chem2025https://conductscience.org/library/papers/39838687PubMed
39521858Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization.Commun Biol2024https://conductscience.org/library/papers/39521858PubMed
38677545
Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application.
J Adv Res2025https://conductscience.org/library/papers/38677545PubMed
38617549Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities.Int J Biol Sci2024https://conductscience.org/library/papers/38617549PubMed
382552142-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor.Biomedicines2024https://conductscience.org/library/papers/38255214PubMed
37175843MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines.Int J Mol Sci2023https://conductscience.org/library/papers/37175843PubMed
36481936Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells.Discov Oncol2022https://conductscience.org/library/papers/36481936PubMed
35719918Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.Front Oncol2022https://conductscience.org/library/papers/35719918PubMed
35093030Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review.Cell Mol Biol Lett2022https://conductscience.org/library/papers/35093030PubMed
34065757Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34065757PubMed
32326336Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.Cancers (Basel)2020https://conductscience.org/library/papers/32326336PubMed
31286834MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.Cell Cycle2019https://conductscience.org/library/papers/31286834PubMed
29876015Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.Oncotarget2018https://conductscience.org/library/papers/29876015PubMed
28373964Altered Mitochondrial Signalling and Metabolism in Cancer.Front Oncol2017https://conductscience.org/library/papers/28373964PubMed
27779188Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway.Sci Rep2016https://conductscience.org/library/papers/27779188PubMed
26698156Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells.Med Oncol2016https://conductscience.org/library/papers/26698156PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CASP7840PubTator's text mininghttps://conductscience.org/library/genes/840NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25566959

GET https://conductscience.org/api/papers/v1/25566959/references?page=2